磁共振引导经尿道超声消融治疗良性前列腺增生:I期研究12个月临床结果
这项I期研究纳入10例因良性前列腺增生需手术的下尿路症状患者,评估MRI引导经尿道超声消融(TULSA)的安全性和可行性。12个月随访显示IPSS中位改善82%,最大尿流率中位改善101%,无严重不良事件,性功能及控尿功能无变化。
要点
- TULSA术后12个月IPSS中位改善82%,最大尿流率中位改善101%。
- 无严重不良事件,控尿、性功能、勃起及肠道功能无变化。
- 术前服用BPO药物的患者术后全部停药。
核心结论
- TULSA对良性前列腺梗阻似乎安全有效,12个月随访结果令人鼓舞,但需更大样本研究确认。
研究设计与样本
- 研究者发起的、前瞻性、注册(NCT03350529)I期研究,纳入10例因良性前列腺增生需手术干预的下尿路症状男性,TULSA后随访12个月。
主要发现
- 基线中位(IQR)年龄68(63-72)岁,前列腺体积53(45-66)mL;6例中度症状,4例重度症状;9例基线使用BPO药物。
- IPSS中位(IQR)从基线17.5(15.3-23.0)降至12个月4.0(2.3-6.3),中位改善82%。
- 最大尿流率中位(IQR)从基线12.4(8.8-17.6)mL/s升至12个月21.8(17.6-26.5)mL/s,中位改善101%。
- 12个月前列腺体积中位缩小33%,PSA中位降低48%;改善在3个月时已出现。
- 12个月时,术前6例射精功能正常者中5例报告正常顺行射精;术前所有服用BPO药物者均停药。
临床怎么用
- TULSA可作为需手术的BPO患者的一种微创治疗选择,术后可停用BPO药物且保留性功能。
局限性
- I期研究样本量小(10例),需更大队列研究确认结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the safety and feasibility of magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) for the treatment of benign prostatic obstruction (BPO). PATIENTS AND METHODS: An investigator-initiated, prospective, registered (NCT03350529), phase I study enrolled men with lower urinary tract symptoms due to benign prostatic hyperplasia in need of surgical intervention. Patients were followed for 12 months after TULSA. Uroflowmetry, prostate-specific antigen (PSA) level, and a comprehensive set of functional questionnaires including the Expanded Prostate cancer Index Composite-26, International Prostate Symptom Score (IPSS) and five-item version of the International Index of Erectile Function were obtained at baseline and every 3 months afterwards. MRI was obtained at baseline, and at 3 and 12 months after TULSA. Medication use before and after TULSA were recorded. Adverse events (AEs) were reported using the Clavien-Dindo classification. RESULTS: A total of 10 men underwent TULSA with no severe AEs encountered. The baseline median (interquartile range [IQR]) age and prostate volume were 68 (63-72) years and 53 (45-66) mL, respectively. At baseline, six patients were moderately symptomatic and four patients severely symptomatic. Nine patients at baseline were on BPO medication. The median (IQR) improvement in the IPSS was 82%, from 17.5 (15.3-23.0) at baseline to 4.0 (2.3-6.3) at 12 months. Similarly, the median maximum urinary flow rate improved by 101%, from a median (IQR) of 12.4 (8.8-17.6) mL/s at baseline to 21.8 (17.6-26.5) mL/s at 12 months. Improvements were already seen at 3 months. The median prostate volume and PSA reduction at 12 months were 33% and 48%, respectively. There were no changes in continence, sexual, erectile or bowel functions. At 12 months, five out of six men with normal ejaculatory function before TULSA reported normal antegrade ejaculations. All patients taking BPO medication before TULSA discontinued medication after TULSA. CONCLUSION: TULSA appears to be a safe and effective treatment for BPO, with promising 12-month follow-up outcomes. Further studies with larger cohorts are needed to confirm the observed results.
引用
- Viitala A, Anttinen M, Wright C, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study. BJU Int. 2021. PMID: 34161649. doi:10.1111/bju.15523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。